These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 7805731

  • 21. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ, Chan HW, Karbach J, Salter RD, Knuth A, Lotze MT, Storkus WJ.
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [Abstract] [Full Text] [Related]

  • 22. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
    Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T.
    Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
    [Abstract] [Full Text] [Related]

  • 23. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG, Turcovski-Corrales SM, Taub DD.
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [Abstract] [Full Text] [Related]

  • 24. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
    Viret C, Davodeau F, Guilloux Y, Bignon JD, Semana G, Breathnach R, Jotereau F.
    Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
    [Abstract] [Full Text] [Related]

  • 25. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.
    Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wölfel T, Boon T, Lethé B.
    Eur J Immunol; 1996 Jan; 26(1):224-30. PubMed ID: 8566071
    [Abstract] [Full Text] [Related]

  • 26. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Feb 15; 160(4):1750-8. PubMed ID: 9469433
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
    Dong HL, Sui YF, Li ZS, Qu P, Wu W, Ye J, Zhang XM, Lu SY.
    Cancer Lett; 2004 Aug 10; 211(2):219-25. PubMed ID: 15219945
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
    Vantomme V, Boël P, De Plaen E, Boon T, van der Bruggen P.
    Cancer Immun; 2003 Dec 10; 3():17. PubMed ID: 14664500
    [Abstract] [Full Text] [Related]

  • 31. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2.
    Ma W, Germeau C, Vigneron N, Maernoudt AS, Morel S, Boon T, Coulie PG, Van den Eynde BJ.
    Int J Cancer; 2004 May 01; 109(5):698-702. PubMed ID: 14999777
    [Abstract] [Full Text] [Related]

  • 32. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
    Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, Appella E, Parmiani G, Marincola FM.
    J Immunol; 1996 May 15; 156(10):3882-91. PubMed ID: 8621927
    [Abstract] [Full Text] [Related]

  • 33. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW, Liu SJ.
    J Immunother; 2012 Apr 15; 35(3):235-44. PubMed ID: 22421941
    [Abstract] [Full Text] [Related]

  • 34. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
    Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG.
    Immunogenetics; 1996 Apr 15; 43(6):377-83. PubMed ID: 8606058
    [Abstract] [Full Text] [Related]

  • 35. Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
    Takaki T, Hiraki A, Uenaka A, Gomi S, Itoh K, Udono H, Shibuya A, Tsuji T, Sekiguchi S, Nakayama E.
    Int J Oncol; 1998 May 15; 12(5):1103-9. PubMed ID: 9538136
    [Abstract] [Full Text] [Related]

  • 36. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
    Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.
    Cancer Res; 2011 Feb 15; 71(4):1253-62. PubMed ID: 21216894
    [Abstract] [Full Text] [Related]

  • 37. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
    Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P.
    Eur J Immunol; 1999 Oct 15; 29(10):3329-37. PubMed ID: 10540345
    [Abstract] [Full Text] [Related]

  • 38. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes.
    Eifuku R, Takenoyama M, Yoshino I, Imahayashi S, So T, Yasuda M, Sugaya M, Yasumoto K.
    Int J Clin Oncol; 2001 Feb 15; 6(1):34-9. PubMed ID: 11706525
    [Abstract] [Full Text] [Related]

  • 39. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
    Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T.
    Proc Natl Acad Sci U S A; 2004 Oct 05; 101 Suppl 2(Suppl 2):14631-8. PubMed ID: 15452345
    [Abstract] [Full Text] [Related]

  • 40. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
    Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A.
    J Exp Med; 1998 Jan 19; 187(2):265-70. PubMed ID: 9432985
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.